This Article Full Text Full Text (PDF) Data Supplement Correction Correction (v116,pe514) All Versions of this Article: 116/16/1784    most recent CIRCULATIONAHA.107.690180v2 CIRCULATIONAHA.107.690180v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Köhler, D. Articles by Eltzschig, H. K. Search for Related Content PubMed PubMed Citation Articles by Köhler, D. Articles by Eltzschig, H. K. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB ADENOSINE 5'-PHOSPHATE Medline Plus Health Information Cardiomyopathy Heart Attack Related Collections Other myocardial biology Cardiovascular Pharmacology Animal models of human disease Genetically altered mice Ischemic biology - basic studies Physiological and pathological control of gene expression Acute myocardial infarction

(Circulation. 2007;116:1784-1794.)
© 2007 American Heart Association, Inc.

Molecular Cardiology

CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia/Reperfusion Injury

David Köhler, PhD^*; Tobias Eckle, MD^*; Marion Faigle, BS; Almut Grenz, MD; Michel Mittelbronn, MD; Stefanie Laucher, BS; Melanie L. Hart, PhD; Simon C. Robson, MD; Christa E. Müller, PhD; Holger K. Eltzschig, MD, PhD

From the Department of Anesthesiology and Intensive Care Medicine (D.K., T.E., M.F., S.L., H.K.E.), Department of Pharmacology and Toxicology (A.G.), and Institute of Brain Research (M.M.), University Hospital, Tübingen, Germany; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital (M.L.H.), and Liver and Transplant Centers (S.C.R.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Pharmaceutical Institute, Pharmaceutical Sciences Bonn, University of Bonn, Bonn, Germany (C.E.M.); and Mucosal Inflammation Program, Department of Anesthesiology, University of Colorado Health Science Center, Denver (H.K.E.).

Correspondence to Holger K. Eltzschig, MD, PhD, Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Campus Box B113, Denver, CO 80262. E-mail holger.eltzschig{at}uchsc.edu

Received January 12, 2007; accepted August 17, 2007.

Background— Extracellular adenosine, generated from extracellular nucleotides via ectonucleotidases, binds to specific receptors and provides cardioprotection from ischemia and reperfusion. In the present study, we studied ecto-enzymatic ATP/ADP-phosphohydrolysis by select members of the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase) family during myocardial ischemia.

Methods and Results— As a first step, we used a murine model of myocardial ischemia and in situ preconditioning and performed pharmacological studies with polyoxometalate 1, a potent E-NTPDase inhibitor (Na₆[H₂W₁₂O₄₀]). Polyoxometalate 1 treatment increased infarct sizes and abolished beneficial effects of preconditioning. To define relative contributions of distinct E-NTPDases, we investigated transcriptional responses of E-NTPDases 1 to 3 and 8 to preconditioning. We noted robust and selective induction of E-NTPDase 1 (CD39) transcript and protein. Histological analysis of preconditioned myocardium localized CD39 induction to endothelia and myocytes. Cd39^–/– mice exhibited larger infarct sizes with ischemia (cd39^+/+ 43.0±3.3% versus cd39^–/– 52%±1.8; P<0.05), and cardioprotection was abrogated by preconditioning (cd39^+/+ 13.3%±1.5 versus cd39^–/– 50.5%±2.8; P<0.01). Heightened levels of injury after myocardial ischemia and negligible preconditioning benefits in cd39^–/– mice were corrected by infusion of the metabolic product (AMP) or apyrase. Moreover, apyrase treatment of wild-type mice resulted in 43±4.2% infarct size reduction (P<0.01).

Conclusions— Taken together, these studies reveal E-NTPDase 1 in cardioprotection and suggest apyrase in the treatment of myocardial ischemia.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				J. Reutershan, I. Vollmer, S. Stark, R. Wagner, K.-C. Ngamsri, and H. K. Eltzschig Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs FASEB J, February 1, 2009; 23(2): 473 - 482. [Abstract] [Full Text] [PDF]

				H. K. Eltzschig, D. Kohler, T. Eckle, T. Kong, S. C. Robson, and S. P. Colgan Central role of Sp1-regulated CD39 in hypoxia/ischemia protection Blood, January 1, 2009; 113(1): 224 - 232. [Abstract] [Full Text] [PDF]

				T. Eckle, D. Kohler, R. Lehmann, K. C. El Kasmi, and H. K. Eltzschig Hypoxia-Inducible Factor-1 Is Central to Cardioprotection: A New Paradigm for Ischemic Preconditioning Circulation, July 8, 2008; 118(2): 166 - 175. [Abstract] [Full Text] [PDF]

				J. C. Morote-Garcia, P. Rosenberger, J. Kuhlicke, and H. K. Eltzschig HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak Blood, June 15, 2008; 111(12): 5571 - 5580. [Abstract] [Full Text] [PDF]

				T. Eckle, M. Faigle, A. Grenz, S. Laucher, L. F. Thompson, and H. K. Eltzschig A2B adenosine receptor dampens hypoxia-induced vascular leak Blood, February 15, 2008; 111(4): 2024 - 2035. [Abstract] [Full Text] [PDF]